Gyre Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm
NEWTOWN SQUARE, PA / ACCESS Newswire (https://www.accessnewswire.com/) / June 29, 2026 / Kaskela Law (https://pr.report/n40a) announces that it is investigating Gyre Therapeutics, Inc. (NASDAQ:GYRE) ("Gyre") on behalf of the company's long-term shareholders. The investigation seeks to determine whether Gyre and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.   Gyre shareholders who would like t
ACCESSWIRE · Jun 29, 2026
Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm
Newtown Square, Pennsylvania--(Newsfile Corp. - May 27, 2026) - Kaskela Law LLC (https://api.newsfilecorp.com/redirect/N3MzoINq8P) is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) ("Gyre") on behalf of the company's long-term shareholders. The investigation seeks to determine whether Gyre and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.   Gyre shareholders who would like to learn more
Newsfile Corp · May 28, 2026
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
* Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases. * China innovation engine provides cost-efficient vehicle for discovery and early-stage development of targeted protein degraders and degrader-antibody conjugates. * Strengthened leadership team in U.S., coupled with China operating presence to support future global growth. SAN DI
Globe Newswire · May 4, 2026

GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm

Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company